Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials

Bibliography

• Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67–71
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2010;9:5–12. quiz e7
   PubMed Web of Science ®Google Scholar
• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2012;108:18–38
   PubMed Web of Science ®Google Scholar
• Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis – clinical characteristics and long-term outcomes. Am J Gastroenterol 1997;92:1501–4
   PubMed Web of Science ®Google Scholar
• Choung RS, Locke GRIII, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012;107:82–8
   PubMed Web of Science ®Google Scholar
• Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203–7
   PubMed Web of Science ®Google Scholar
• Coulie B, Tack J, Peeters T, et al. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998;43:395–400
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1461–3
   PubMed Web of Science ®Google Scholar
• Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1464–86
   PubMed Web of Science ®Google Scholar
• Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40–52
   PubMed Web of Science ®Google Scholar
• Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009;30:707–17
   PubMed Web of Science ®Google Scholar
• Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther 2014;39:923–39
   PubMed Web of Science ®Google Scholar
• Bajor A, Törnblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015;64:84–92
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015;41(5):438–48
   PubMed Web of Science ®Google Scholar
• Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. Gut 2012;61:1132–9
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(Suppl 1):S2–26. quiz S27
   PubMed Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI, et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383–94
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):S11–18
   PubMed Web of Science ®Google Scholar
• Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 2005;313:1397–405
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089–96
   PubMed Web of Science ®Google Scholar
• Peeters TL. New motilin agonists: a long and winding road. Neurogastroenterol Motil 2006;18:1–5
   PubMed Web of Science ®Google Scholar
• Sanger GJ. Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil 2014;26:149–55
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009;21:657–64. e630-51
   PubMed Web of Science ®Google Scholar
• Leming S, Broad J, Cozens SJ, et al. GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011;23:958–e410
   PubMed Web of Science ®Google Scholar
• Broad J, Mukherjee S, Samadi M, et al. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012;167:763–74
   PubMed Web of Science ®Google Scholar
• Cremonini F, Camilleri M, Vazquez Roque M, et al. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology 2006;131:1431–9
   PubMed Web of Science ®Google Scholar
• Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009;6:343–52
   PubMed Web of Science ®Google Scholar
• Karasawa H, Pietra C, Giuliano C, et al. New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson’s disease. Neurogastroenterol Motil 2014;26:1771–82
   PubMed Web of Science ®Google Scholar
• Van der Ploeg L, Laken H, Sharma S, et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci 2014;109:20–9
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41–8
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11:1453–9
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum RW, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146(Suppl 1):S158–9
   Google Scholar
• Acosta A, Kolar G, Iturrino J, et al. A phase II, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to evaluate the efficacy, safety, and pharmacodynamics of RM 131 in patients with chronic constipation. Gastroenterology 2014;146(Suppl 1):S364
   Google Scholar
• Acosta A, Boldingh A, Busciglio I, et al. Motor effects of relamorelin on colonic motor functions in patients with chronic constipation: a randomized, placebo-controlled, double-blind trial. Abstract submitted to the Annual Meeting of the American Gastroenterological Association; May 2015, Washington, DC
   Google Scholar
• Marek GJ, Carpenter LL, McDougle CJ, et al. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003;28:402–12
   PubMed Web of Science ®Google Scholar
• Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol 2014;306:G796–801
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for GI disorders. Aliment Pharmacol Ther 2012;35:745–67
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99–112
   PubMed Web of Science ®Google Scholar
• Goldberg M, Li YPP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010;32:1102–12
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39:239–53
   PubMed Web of Science ®Google Scholar
• Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Gilet M, Eutamene H, Han H, et al. Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation. Neurogastroenterol Motil 2014;26:1761–70
   PubMed Web of Science ®Google Scholar
• McKinnell RM, Armstrong SR, Beattie DT, et al. Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett 2013;23:4210–15
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011;2:25
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013;58:2580–6
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Talluto C, Foss JA, et al. Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation. Am J Gastroenterol 2010;105:S487–8
   Google Scholar
• Miner PB, Surowitz R. Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12-week, multi-center trial. Gastroenterology 2013;144:S163
   Web of Science ®Google Scholar
• Spencer AG, Jacobs JW, Leadbetter MR, et al. RDX5791, a first-in-class minimally systemic NHE3 inhibitor in clinical development for CIC and IBS-C, increases intestinal sodium leading to enhanced intestinal fluid volume and transit. Gastroenterology 2011;140:S99
   Google Scholar
• Eutamene H, Charmot D, Navre M, et al. Visceral antinociceptive effects of RDX5791, a first-in-class minimally systemic NHE3 inhibitor on stress-induced colorectal hypersensitivity to distension in rats. Gastroenterology 2011;140:S57–8
   Google Scholar
• Bulmer DC, Grundy D. Achieving translation in models of visceral pain. Curr Opin Pharmacol 2011;11:575–81
   PubMed Web of Science ®Google Scholar
• Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002;14:221–7
   PubMed Web of Science ®Google Scholar
• Sabaté JM, Bouhassira D, Poupardin C, et al. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008;20:134–41
   PubMed Web of Science ®Google Scholar
• Armstrong SR, Campbell CB, Richardson CL, et al. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol 2013;386:471–8
   PubMed Web of Science ®Google Scholar
• Vickery R, Li YP, Kohler R, et al. TD-1211 demonstrates constipation-relieving effects, including decrease in rescue laxative use, in patients with opioid-induced constipation. Am J Gastroenterol 2011;106(Suppl 2):1341–2
   Google Scholar
• Vickery R, Li YP, Schwertschlag U, et al. TD-1211 demonstrates improvement in bowel movement frequency without impacting analgesia in a Phase 2b study of patients with opioid-induced constipation. Pain Week, Las Vegas, NV, September 5–8, 2012. Poster #121 Available from: http://www.painweek.org/scientificposters/2012-accepted-abstracts
   Google Scholar
• Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol 2014;7:167–75
   PubMed Web of Science ®Google Scholar
• Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study. Aliment Pharmacol Ther 2011;34:41–50
   PubMed Web of Science ®Google Scholar
• Camilleri M. Invited Review: Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol 2014;8:49–61
   PubMed Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106:1803–12
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154–64
   PubMed Web of Science ®Google Scholar
• Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015;41:54–64
   PubMed Web of Science ®Google Scholar
• Revicki DA, Camilleri M, Kuo B, et al. Development and content validity of a Gastroparesis Cardinal Symptom Index daily diary. Aliment Pharmacol Ther 2009;30:670–80
   PubMed Web of Science ®Google Scholar
• Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the gastroparesis cardinal symptom index-daily diary (GCSI-DD). Neurogastroenterol Motil 2012;24:456–63. e215-e6
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95
   PubMed Web of Science ®Google Scholar
• Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010;87:748–53
   PubMed Web of Science ®Google Scholar
• Camilleri M, Shin A, Busciglio I, et al. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014;26:1677–85
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015;41:438–48
   PubMed Web of Science ®Google Scholar
• Camilleri M. Ten secrets for development of drugs for functional gastrointestinal diseases. Comment from the Editors Gastroenterology 2000;118:653
   PubMed Web of Science ®Google Scholar